Sangamo Therapeutics Inc., a genomic medicine company, has reported business highlights and second quarter 2024 financial results.   Revenues for the second quarter ended June 30, 2024 were $0.3 million, compared to $6.8 million for the same period in 2023, a decrease of $6.5 million.   This decline was primarily attributed to decreases of $2.4 million and $2.2 million in revenues relating to Sangamo’s prior collaboration agreements with Biogen and Novartis, respectively, due to the terminat...